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1  | HUMAN SKIN: MORE THAN JUST A 
PHYSIC AL BARRIER
To understand the need and requirements of models to study the 
skin barrier function, it is important to first address the different 
barrier functions of human skin and their role in maintaining tissue 
homeostasis. From the outside- in, the skin protects against diffu-
sion of molecules, chemical exposure, ultraviolet (UV) radiation and 
penetration of pathogens. From the inside- out, passage of water 
and electrolytes is prevented thereby protecting the body from 
dehydration. The stratum corneum (SC) and tight junctions (TJs) form 
the physical barrier.[1,2] While the SC exerts most of the defensive 
functions of the epidermis from outside- in, TJs are the first physical 
barrier from inside- out. In case of a barrier defect, the Langerhans 
cells, keratinocytes and skin resident immune cells join forces to 
provide a secondary immunological barrier. The release of defense 
molecules by epidermal keratinocytes contributes to the chemical 
barrier function of the skin. Last but not least, the skin microbiome 
can be considered as a microbial barrier. We will briefly outline these 
four barrier functions which are illustrated in Figure 1.
 
Accepted: 19 February 2018
DOI: 10.1111/exd.13531
R E V I E W
3D skin models for 3R research: The potential of 3D 
reconstructed skin models to study skin barrier function
Hanna Niehues1 | Joke A. Bouwstra2 | Abdoelwaheb El Ghalbzouri3 |  
Johanna M. Brandner4 | Patrick L. J. M. Zeeuwen1 | Ellen H. van den Bogaard1
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, 
provided the original work is properly cited.
© 2018 The Authors. Experimental Dermatology Published by John Wiley & Sons Ltd
1Department of Dermatology, Radboud 
university medical center (Radboudumc), 
Radboud Institute for Molecular Life 
Sciences (RIMLS), Nijmegen, The Netherlands
2Division of Drug Delivery Technology, 
Cluster BioTherapeutics, Leiden Academic 
Centre for Drug Research, Leiden University, 
Leiden, The Netherlands
3Department of Dermatology, Leiden 
University Medical Center, Leiden,  
The Netherlands
4Department of Dermatology and 
Venerology, University Hospital Hamburg-
Eppendorf, Hamburg, Germany
Correspondence
Ellen H. van den Bogaard, Department of 
Dermatology, Radboud university medical 
center (Radboudumc), Radboud Institute for 
Molecular Life Sciences (RIMLS), Nijmegen, 
The Netherlands.
Email: Ellen.vandenbogaard@radboudumc.nl
Funding information
The Netherlands Organization for Health 
Research and Development; ZonMw TOP, 
Grant/Award Number: 91211052; ZonMw 
VENI, Grant/Award Number: 91616054; 
ZonMw MKMD, Grant/Award Number: 
114021503
Abstract
The skin barrier is an important shield regulating the outside- in as well as inside- out 
penetration of water, nutrients, ions and environmental stimuli. We can distinguish 
four different barrier compartments: the physical, chemical, immunological and mi-
crobial skin barrier. Well- functioning of those is needed to protect our body from the 
environment. To better understand the function and the contribution of barrier dys-
function in skin diseases, 3D skin or epidermal models are a valuable tool for in vitro 
studies. In this review, we summarize the development and application of different 
skin models in skin barrier research. During the last years, enormous effort was made 
on optimizing these models to better mimic the in vivo composition of the skin, by 
fine- tuning cell culture media, culture conditions and including additional cells and 
tissue components. Thereby, in vitro barrier formation and function has been im-
proved significantly. Moreover, in this review we point towards changes and chances 
for in vitro 3D skin models to be used for skin barrier research in the nearby future.
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1.1 | Physical barrier
The SC consists of about 15- 20 stacked layers of corneocytes with 
intermediate lipid layers. During the terminal differentiation process, 
viable keratinocytes transform into dead and dying cells that have 
lost their nuclei and cytoplasmic organelles, which are now called 
corneocytes. Terminal differentiation of keratinocytes is tightly con-
trolled and enzymes like transglutaminases (TGases)[3] and protease 
inhibitors like cystatin M/E control the cornification and desquama-
tion process.[4] The lipids form an integral part of the physical barrier, 
and the final steps in synthesizing the lipids occur at the interface 
between the viable epidermis and SC. During the differentiation 
process, keratinocytes express distinct epidermal proteins in the dif-
ferent layers of the epidermis. This feature is very useful for the dis-
tinction of the layers within the epidermis of human skin models and 
to check whether the in vitro generated epidermis faithfully mimics 
native skin. Additionally, the viable epidermis also contributes to the 
skin barrier function by adherens junctions, TJs and desmosomes. 
Adherens junctions and desmosomes are not directly linked to skin 
barrier function but are important for keratinocyte adhesion and 
differentiation that is needed for epidermal integrity. TJs are crucial 
for skin barrier function as they are crucial for the inside- out barrier 
function.[5,6] TJs are formed in the granular cell layer by several TJ 
proteins that are all expressed at specific layers of the epidermis, 
indicating the complexity of the skin barrier formation.[7]
1.2 | Chemical barrier
The skin is equipped with antimicrobial peptides (AMPs), pro-
duced by the keratinocytes, but also immune cells, that protect 
against bacterial infections. The most well- known keratinocyte- 
derived AMPs are defensins, S100 proteins, human cathelicidin 
LL- 37 and late cornified envelope proteins. Other skin AMPs are 
dermcidin, SKALP/elafin and secretory leukoprotease inhibitor 
(SLPI). Most of these AMPs are absent or expressed at low levels 
during skin homeostasis. In more vulnerable areas like the hair 
follicles (port d’entrée) or internal epithelia (oral cavity, vagina), 
these AMPs are expressed at higher levels to contribute to host 
defense.[8]
The antimicrobial activity of reactive oxygen species (ROS) re-
leased by keratinocytes contributes to the chemical skin barrier but 
may also harm the host, for example when produced by excessive 
UV radiation. For protection, the skin produces antioxidants like vi-
tamins C and E, and glutathione[9-11] and produces ROS scavengers 
(eg superoxide dismutase, catalase, peroxidase). Additionally, it was 
shown that small proline rich (SPRR) proteins are highly effective 
in quenching ROS in the epidermal cornified cell envelope, thereby 
contributing to epidermal protection.[12]
1.3 | Immunological barrier
In the dermis but also in the epidermis, cells and molecules from 
either the innate or adaptive immune system are present to protect 
against a large variety of pathogens, for example via the expression 
of pattern recognition receptors that can bind microbial- derived li-
gands to induce an immune response. Not only immune cells, like 
Langerhans cells or patrolling T cells in the epidermis, contribute 
to epidermal host defense, but also keratinocytes are potent pro-
ducers of soluble immunomodulatory factors, like cytokines and 
chemokines that lead to or dampen inflammation, or can modulate 
T cells and dendritic cells.[13] The interplay between keratinocytes 
and immune cells is vital for tissue homeostasis and inflammatory 
processes, and has been the subject of research for decades. In 
the skin, there are twice as much T cells present than in the blood-
stream,[14] indicating the importance of the skin as an immunologi-
cal reservoir.
1.4 | Microbial barrier
The microbial barrier is formed by the commensal skin microbiome. 
The skin microbiome is defined as all microbiota that are present on 
our skin, mainly consisting of bacteria but also including fungi and 
viruses. Our skin commensals serve as a barrier to prevent infection 
by pathogenic microbes. A well- balanced microbiome contributes 
to our health, and it is shown that imbalance, with a shift towards 
pathogenic microbiota, is related to disease.[15,16] The complex host- 
microbe and microbe- microbe interactions on the surface of human 
skin, in health and disease, are poorly understood and subject of cur-
rent research.
F IGURE  1 Skin barrier compartments. The human epidermal 
barrier can be divided into four compartments: the physical, 
chemical, immunological and microbial barrier. The schemes show 
the most important cells, molecules or micro- organisms that 
contribute to each particular barrier function and where those 
are located within the different epidermal layers (SC = stratum 
corneum, SG = stratum granulosum (black dots represent 
keratohyalin granules), SS = stratum spinosum, SB = stratum 
basale)
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2  | RE VIE W OUTLOOK AND AIMS
To study skin barrier function in health and disease, we need model 
systems in which normal skin biology and the effect of disease- related 
factors can be studied. The search for appropriate in vitro skin models 
has started decades ago and is ever rising due to limited availability of 
human skin, and ethical issues with regard to animal experimentation. 
While in vitro 3D skin models have been extensively used to study the 
physical barrier of the skin, the chemical barrier function of the epi-
dermis with regard to AMPs or ROS- neutralizing molecules is less well 
studied. Although it is common knowledge that antimicrobial peptides 
are produced and secreted by keratinocytes, functional studies are 
lacking mainly due to the very few studies describing the incorporation 
of microbiota in 3D skin models. This is, however, a crucial step to take 
in the coming years. The same holds true for the immunological skin 
barrier. Three- dimensional skin models including immune cells like T 
cells or Langerhans cells have been reported[17-20]; however, it is chal-
lenging to mimic the dynamic patrolling of immune cells between the 
skin and the lymphatic system in a static in vitro system. Current devel-
opments to generate skin- on- a- chip platforms by microfluidics tech-
nology could enable the analysis of the immunological barrier function 
by immune cells that recognize and eliminate pathogens in the skin.[21]
In this review, we will discuss the development of 3D skin models 
over the years and highlight the potential of these models to study 
the physical and microbial barrier function of the skin. With this 
overview, we aim to provide a direction for future research in these 
fields and to enable studies on the chemical and immunological bar-
rier as well.
3  | THE DE VELOPMENT OF IN VITRO 
3D MODEL S FOR HE ALTHY SKIN: AN 
HISTORIC AL OVERVIE W
The first methods that describe the separation of human skin (epi-
dermis from the dermis) and the isolation and culturing of human ke-
ratinocytes were developed in the early fifties and lie at the heart of 
the knowledge we have today to generate reconstructed skin mod-
els.[22] Cultivation of adult mammalian skin epithelium in vitro was 
described for the first time in 1948[23] and was subsequently adapted 
by other groups.[24] It was demonstrated that cell suspensions ob-
tained from slices of human epidermis after trypsinization can un-
dergo long- term culture; however, the epithelial like cells showed 
more resemblance with HeLa cells than keratinocytes.[25] In 1960, 
it was shown that isolated keratinocytes from adult guinea pig skin 
were able to form colonies in culture, even in the absence of a der-
mal support, when seeded at high a density, while under submerged 
conditions cells seeded at lower densities had a tendency to differ-
entiate.[24] A huge milestone was achieved by Rheinwald and Green 
in 1975 who used lethally irradiated 3T3 fibroblasts as feeder layers 
to generate cultures of human keratinocyte colonies that originated 
from a single keratinocyte. This discovery allowed scientists in the 
field of dermatology to generate large quantities of keratinocytes 
for in vitro cell culture studies and paved the way for the treatment 
of burn wound patients.[26-29] Initiated by the seminal work of the 
Rheinwald and Green laboratory, the monolayer culture of human 
keratinocytes on plastic culture plates has been the main technique 
to study skin biology and pathophysiology in vitro. Rheinwald and 
Green were also the first to describe that such monolayer cultures 
can differentiate and form multilayered structures.[30] Simplicity, 
high- throughput and reproducibility are major advantages of mon-
olayer keratinocyte cultures. However, many features of a fully strat-
ified epidermis are lacking in this model and keratinocytes are forced 
to adapt to artificial circumstances, like a flat surface and submerged 
culture, which may alter gene expression and cell function.[31] To 
study cell- cell interactions, regulation of proliferation and differen-
tiation, wound healing, skin barrier function and skin- microbiome 
interactions, 3D skin models better resemble the natural architec-
ture and functions of the skin and should be considered as the gold 
standard when performing in vitro studies on human skin.
One of the first explant 3D model was described in 1976 when 
inverted dead pig skin was used to establish outgrowth of keratino-
cytes.[32] This method was improved by the use of collagen matrices to 
culture keratinocytes at the air- liquid interface.[33,34] This study set the 
stage for generating a better differentiated epidermis on human de- 
epidermized dermis (DED) while preserving the basement membrane 
proteins.[35] Ponec et al further improved this DED to culture kera-
tinocytes that attach to the existing basement membrane.[36] From 
the eighties on, culture protocols were optimized and improvements 
were made resulting in many different types of human skin equivalents 
(HSEs) and human epidermal equivalents (HEEs), also designated as 
organotypic cultures, cultured skin substitutes or living skin equiva-
lent, with different types of dermal substrates (eg inert filters, DED, 
collagen matrices, lyophilized collagen- glycosaminoglycan GAG mem-
branes and fibroblast derived matrices)[37-42] (Figure 2). HSEs serve 
as an excellent alternative to animal experimentation, which resulted 
(due to public pressure) in 2013 in the ban of testing cosmetic ingre-
dients in animals. Nowadays, different types of HSEs exist harbouring 
other cell types like melanocytes, endothelial cells, Langerhans cells 
and immune cells.[20,43-45] These enriched HSEs are mostly used for 
research purposes to study interactions between cells and their micro-
environment and open new opportunities in the field of tissue engi-
neering and wound healing.[46-48] Next to the “in- house” HSEs, several 
commercial skin equivalents are available such as EpiCS® (CellSystems, 
Germany), Epiderm™ (MatTek, USA) and SkinEthic™ RHE (L’Oreal, 
France), that are used for basic research and toxicological screen-
ings.[49-52] These models have been validated according to European 
(EU) guidelines and implemented into the EU and Organisation for 
Economic Co- operation and Development (OECD) guidelines for 
testing dangerous ingredients for the skin.[49,53-58] Currently, the 
Organisation for Economic Co- operation and Development (ECVAM) 
is also putting effort in replacing the local lymph node assay (LLNA) 
by HSEs to predict and discriminate between skin sensitizers and irri-
tants.[59-62] At present, the development of HSEs is accelerated due to 
novel technologies such as 3D printing and skin (organ) on a chip.[63-
65] These technological advances enable the combination of multiple 
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cell types and a dynamic fluid flow, but it remains to be seen whether 
optimal skin morphology and function can be achieved and monitored 
in these technical platforms. It will be of utmost importance to validate 
these novel skin models and determine their suitability to study skin 
barrier function like it has been carried out for the past decades for the 
HSEs and HEEs, which we will discuss below.
4  | 3D SKIN MODEL S TO STUDY THE 
PHYSIC AL SKIN BARRIER:  FROM STR ATUM 
CORNEUM LIPIDS TO TIGHT JUNC TIONS
4.1 | Stratum corneum lipid composition of native 
skin and differences with 3D skin models
A major part of the physical barrier function of the skin resides in the 
SC consisting of corneocytes embedded in lamellar regions. As the 
intercellular SC lipids are crucial for a proper skin barrier function, this 
section focuses on the lipid barrier as an important part of the physi-
cal skin barrier. The major lipid classes are ceramides, free fatty acids 
(FFAs) and cholesterol.[66] The lipid assembly of native human skin is 
mainly orthorhombic, which is further explained in Figure 3.[67-69] In 
a first attempt to create a skin barrier, keratinocytes were seeded on 
collagen gels or collagen- coated filters and cultured at the air- liquid 
interface, but the SC was not properly formed.[35] Next, keratino-
cytes were combined with human de- epidermized dermis[35,70-73] or 
collagen gels populated with fibroblasts[72,74] which improved tissue 
architecture, lamellar body extrusion and the SC formation.[75,76] 
However, lipid assembly was yet not optimal.[67,75] Further optimiza-
tion by vitamin C supplementation substantially improved the lipid 
processing and resulted for the first time in the synthesis of also 
the most hydrophilic ceramide subclasses although in slightly differ-
ent composition than in native human skin.[77-81] In the same period, 
the lipid composition and organization of various commercial was 
reported (eg EpiDerm, SkinEthic, EpiSkin).[82] Substantial differences 
were observed between the models, but at that time, none of them 
contained the hydrophilic ceramide subclasses in amounts similar to 
native skin, indicative for a lack of vitamin C in the culture medium. 
Importantly, the permeability of each of these models was much 
higher than in native human skin.[83]
In the stratum corneum of HSEs, the chain length of FFAs is 
shorter when compared to native human skin,[84] but improvement 
of the lipid profile has been achieved by the supplementation of 
F IGURE  2 Skin barrier analyses in 3D skin models.(A) After 
skin biopsy, the epidermis can be separated from the dermis to 
isolate both keratinocytes and fibroblasts. To generate a 3D skin 
model keratinocyte can be grown on a cellular matrix (fibroblast- 
collagen matrix), acellular matrix (de- epidermized dermis, DED) or 
inert plastic filter. For several days, the keratinocytes are grown 
in submerged cell culture after which the culture medium level is 
lowered for culture at the air- liquid interface. About two weeks 
later, a multilayered stratified epithelium is formed which is similar 
to in vivo skin/epidermis. (B) List of diverse read out parameters 
that can be assessed to determine the skin barrier function of in 
vitro skin models
F IGURE  3 Stratum corneum lipid organization. In the 
intercellular spaces between the corneocytes, the lipids are 
arranged in stacked layers (lamellae), with two coexisting lamellar 
phases, either 6 nm (SPP) or 13 nm (LPP). Within the lipid lamellae, 
the lipids are arranged in a very dense ordered orthorhombic 
organization, a less dense ordered hexagonal organization or a 
disordered liquid organization. The former is predominantly present 
in healthy human SC. The figure has been adopted from J. van 
Smeden, thesis June 2013 entitled: A breached barrier:analysis of 
stratum corneum lipids and their role in eczematous patients
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fatty acids in the medium.[84] More recently, two different HSE and 
one HEE model and their ceramide profiles were examined.[81,85] 
These models showed all a similar ceramide profile: all ceramide sub-
classes identified in native human SC were present, but the relative 
amounts differed from that in native human skin. The permeability 
of these models was 3- 5 times higher than in native human skin.[86] 
Another HSE model shows the presence of ceramide [NS], [NdS] and 
[NP], but the most hydrophilic ceramides were hardly not detected 
suggesting absence of vitamin C in the medium.[86] For a representa-
tion of different ceramide classes, see Figure 4.
With the introduction of liquid chromatography- mass spectrom-
etry (LC/MS), the lipid composition could be evaluated in more de-
tail.[87] This revealed that HSEs have an increased abundance of short 
chain ceramides and an increased level of unsaturated chains.[87,88] 
This leads to organization alterations including a less dense hexago-
nal packing and shorter repeat distance of the lamellar phases com-
pared to native human skin. The SkinEthic and Phenion skin models 
were also examined. The SkinEthic model had a similar lipid profile 
as the Leiden models with improved ceramide profile compared to 
previous studies,[82] while the Phenion model showed very low cera-
mide content lacking the most hydrophilic ceramides and high levels 
of unsaturated FFAs (unpublished results).
The presence of shorter chains and unsaturated lipids is very 
important observations as this provides important information to 
improve the lipid composition and thus the lipid barrier in culture 
models. Furthermore, modifications of the environmental condi-
tions including the optimization of culture temperature both in 2D 
and 3D can be of influence. Recent evidence revealed the influ-
ence of reducing the relative humidity.[89-91] Recently, chitosan was 
introduced in the collagen matrix, which resulted in an improved 
skin barrier as evaluated by measurement of transepidermal water 
loss.[92] Optimization of culture conditions will be topic of future 
studies. Medium composition is also prone to optimization, as 
multiple studies revealed improved barrier formation after topical 
application of metabolic active molecules improving the barrier for-
mation in vivo.[93-95] These molecules could potentially be applied on 
or dissolved in the medium of HSEs to enhance the in vitro barrier 
functionality. At first, the actual barrier function of the HEEs and 
HSEs is of importance. Nowadays, many commercial and in- house 
skin models show a well- developed epidermis; however, their use in 
screening constituents and formulations on their permeation across 
the skin is yet limited.[52,96] The main reason for this limitation is the 
difference in lipid composition and organization when compared to 
native skin. To conclude, improvement of the skin barrier function, 
can be achieved by (i) normalization of ceramide subclass composi-
tion, (ii) increase in CER and FFA chain length and (iii) reduction in 
the level of monounsaturated fatty acids and unsaturated CERs. The 
optimization of the culture medium and a more in vivo like culture 
environment concerning humidity, temperature and oxygen levels 
are important factors to take into account. Furthermore, it could be 
of interest to add sebocytes in the 3D models to initiate the pro-
duction of sebum to modify the surface properties and more closely 
mimic the interactions of formulations with the skin surface in the 
in vivo situation.
4.2 | Human skin models to study the role of tight 
junctions in skin barrier function
The next physical barrier in the skin, just beneath the stratum cor-
neum, is formed by the tight junctions (TJs) in the epidermis. In re-
cent years, it became evident that TJs are part of the physical skin 
barrier.[5,7,97] In addition, they influence SC formation and func-
tion.[6,7] Furthermore, TJ proteins have been shown to be involved in 
keratinocyte proliferation, differentiation, migration, apoptosis and 
cell- cell adhesion.[98-101] Thus, TJs and distinct TJ proteins are inter-
esting to address for investigation of epidermal barrier function, epi-
dermal differentiation, epidermal ion gradients and wound healing.
In well- formed reconstructed HEEs and HSEs, localization of TJ 
proteins is similar to normal skin; that is, claudin- 1 (Cldn- 1) is found 
in all epidermal layers with a lower expression in the basal cell layer, 
Cldn- 4 and ZO- 1 are localized in the upper stratum spinosum (SS) 
and stratum granulosum (SG), and occludin is restricted to the gran-
ular cell layer.[102,103] In addition, TJ barrier function to molecular 
tracers can nicely be seen in the granular cell layer by Biotin- SH as-
says in well- structured models, again similar to human skin.[102-108] 
However, when the model is less developed, atypical localizations 
can be seen. TJs also contribute to transepithelial electrical resis-
tance (TEER) often measured in 3D models, but TEER also reflects 
ion barrier of the SC and is therefore a measure for overall barrier 
function.
In general, HEEs and HSEs are elegant models to investigate TJ 
formation and function in the epidermis. For example, HEEs were 
F IGURE  4 Overview of ceramide classes. Ceramides consist 
of a polar head group and two apolar tails, a sphingoid base linked 
to an acyl chain (grey). Both chains can vary in their structure by 
the number of carbon atoms and the head group architecture as 
shown in the figure. In the most abundant ceramides in human SC, 
4 different sphingoid bases (dihydrosphingosine [dS], sphingosine 
[S], phytosphingosine [P] and 6- hydroxy sphingosine [H]) and 3 
different acyl chains (non- hydroxy fatty acid [N], α- hydroxy fatty 
acid [A] and esterified ω- hydroxy fatty acid [EO]) are present. The 
figure has been adopted from J. van Smeden, thesis June 2013 
entitled: A breached barrier:analysis of stratum corneum lipids and 
their role in eczematous patients
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used already very early during epidermal TJ research to investi-
gate the formation of TJs during epidermal maturation. In addition, 
HEEs and HSEs were instrumental to investigate the effect of (i) 
Clostridium perfringens enterotoxin, a toxin which is known to open 
TJs in the intestine by removal of—among others—Cldn- 3, Cldn- 4 
and Cldn- 7,[109] (ii) sodium caprate (C10), a molecule well known as 
an absorption enhancer in the intestine which influences signalling 
pathways and thereby opens TJs,[106,110] and (iii) knock- down of the 
TJ protein occludin.[98] On the other hand, 3D skin models have 
been used to investigate the influence of external stimuli or non- TJ- 
protein mutations on TJs. The models were used to test the effect of 
(i) various cytokines and combinations of cytokines,[103,107,111-113] (ii) 
histamine,[105] (iii) staphylococcal infection,[102] (iv) TLR agonists,[108] 
(v) cells derived from squamous cell carcinoma and actinic kerato-
sis[114] and (vi) filaggrin mutations/knock- down.[103,112,115]
4.3 | Technical and biological variances in 3D 
skin models
Notwithstanding the great importance of the implementation of 3D 
skin models in skin barrier research, we should be aware that experi-
mental heterogeneity and the wide variety in types of skin models 
based on cell sources, cell types, dermal substrates, culture medium, 
etc. hamper the replication of data. Raising awareness about biologi-
cal variances is of great importance, and the use of multiple differ-
ent biological donors (albeit resulting in larger standard deviations) 
within experiments is highly recommended. Furthermore, a thor-
ough characterization of the basic model is required to evaluate the 
effects of interventions. The use of patient- derived, genetically de-
fined keratinocytes or the overexpression or knock- down of genes 
is considered a valuable tool for the functional analysis of individual 
genes in an organ- like environment. However, differences in experi-
mental procedures may impact the study outcome, which is exempli-
fied in the next paragraph by the variety of 3D skin models to study 
the role of filaggrin (FLG) in skin barrier function.
4.4 | Studying skin barrier function in human skin 
diseases: the filaggrin story as an example
Skin barrier dysfunction is associated with several skin disorders 
caused by mutations encoding the main components of corneo-
cytes, the lipid layers, or cell- to- cell contacts like desmosomes or 
TJs.[116] Besides these monogenic diseases, impaired skin barrier 
function can be a secondary event in chronic skin inflammation (eg 
psoriasis, atopic dermatitis). One key example of studies on the role 
of skin barrier function in skin disease pathogenesis is that of FLG in 
atopic dermatitis (AD). FLG- null alleles are by far the strongest and 
most widely replicated genetic risk factor for AD. As sensitization 
against common environmental antigens is a hallmark of AD, it has 
been tempting to postulate a leaky skin barrier as the most plausible 
mechanism that links genetic alterations to the disease phenotype. 
Murine models of FLG haplo- insufficiency, showing barrier impair-
ment and enhanced percutaneous allergen sensitization, exemplify 
the detrimental effect of having less FLG expression on skin barrier 
function.[117] The impaired barrier integrity phenotype associated 
with FLG- null mutations in human skin is emerging, with evidence of 
reduced natural moisturizing factor (NMF) in the SC,[118-120] and SC 
integrity and cohesion impairment.[121,122] As mouse models may not 
faithfully recapitulate the human pathophysiology, in vitro models 
seem a promising tool to dissect the effect of FLG loss on skin barrier 
function in a controlled laboratory environment.
Over the years, several studies have appeared using knock- down 
strategies in 3D skin models to study the effect of FLG on skin bar-
rier function. The majority of these models are based on the model 
first described by Mildner et al who used neonatal human foreskin 
keratinocytes and siRNA to knock- down FLG gene expression and 
observed an increased penetration of the Lucifer Yellow (LY) dye 
through the SC of FLG knock- down HEEs.[123] Thereafter, studies 
from other groups appeared using similar approaches; however, 
results are conflicting. Experimental models have used foreskin 
keratinocytes,[87,122-124] adult primary keratinocytes[125] or an im-
mortalized keratinocyte cell line[126] to generate HSEs. Knock- down 
strategies varied from transient knock- down using siRNA[87,122-124] 
to stable transduction using lentiviral delivery of FLG- targeting 
shRNA.[125,127] Most of these studies obtained a significant reduc-
tion in FLG mRNA or protein expression (70%- 90%), but none of 
them reached complete absence of expression. More recently, we 
and others have used patient- derived keratinocytes obtained from 
ichthyosis vulgaris (IV) patients carrying homozygous FLG loss- of- 
function mutations to generate HEEs and study in vitro skin barrier 
function.[103,127] This provides a unique possibility to study the role 
of FLG in skin barrier defects, reported for both IV and AD. Thereby, 
knock- down–derived off- target effects were excluded, while poten-
tial compensatory mechanisms by naturally occurring FLG deficiency 
were taken into account. Strikingly, no differences were found in the 
barrier function of the naturally FLG- deficient 3D skin models. FLG 
mutations only explain a subgroup of all AD patients, whereas all 
patients suffer from barrier impairment; therefore, there must be 
one or more additional factors than FLG mutations alone. Probably, 
other mutations or exogenous triggers might be necessary to induce 
AD, either accompanied by or resulting in an impaired skin barrier 
function. The advantage of the use of a 3D model was to specifically 
modify one parameter, in this case the use of FLG- deficient keratino-
cytes, to analyse the consequences thereof on the development and 
function of the epidermal barrier in vitro. Similarly, no changes were 
observed in the barrier permeability and lipid composition of FLG 
knock- down keratinocytes in a 3D model.[126] In our study, barrier 
function was tested by the polar solutes LY and biotin as these are 
commonly used in comparable studies.[125,128] Although alteration of 
the permeability for these low molecular weight tracers was not ob-
served, this does not completely rule out alterations of FLG- deficient 
epidermis with respect to permeability for environmental molecules 
with other biophysical properties such as microbial or airborne an-
tigens, or fragments thereof. This raises an important question: can 
we draw definite conclusions with the 3D skin models we are using 
when complex disease pathogenesis lies at the heart of the disease? 
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This concern also applies to in vivo animal models, and we should 
therefore strive to combine insights gathered from different exper-
imental models for a better validation and extrapolation of results 
towards complex human diseases.
5  | THE SKIN MICROBIOME: A NOVEL 
PL AYER IN SKIN BARRIER RESE ARCH
Besides the above- mentioned barrier compartments of the skin, the 
microbial barrier is of great importance.[129] Disturbance of any of 
these barriers can lead to a persistent inflammatory state or an in-
sufficient host response to pathogens. Over the recent years, we 
have witnessed a scientific breakthrough with respect to our knowl-
edge and understanding of the human skin microbiome.[130-137] In 
normal circumstances, our skin peacefully coexists with commen-
sal bacteria; however, changes in the composition of cutaneous mi-
crobial communities (which is called dysbiosis) and an altered host 
immune response to these microbiota can affect the homeostatic 
relations. This disturbance might drive inflammatory skin diseases 
like psoriasis and AD, which are characterized by an impaired skin 
barrier function.[129,138-140] Mutations in the FLG gene are the major 
genetic risk factor for developing AD,[141] and recently, it was demon-
strated that FLG mutations also have a strong impact on the human 
skin microbiome.[16] Cutaneous micro- organisms are linked to the 
pathogenesis of AD as skin of these patients is frequently colonized 
with Staphylococcus (S.) aureus leading to recurrent skin infections 
and subsequent antibiotic treatment.[142,143] A study using HSE mod-
els has shown that reduced expression of filaggrin protein resulted 
in increased epidermal S. aureus colonization.[144] S. aureus is also a 
major pathogen in skin infections in burn wound patients, and large 
efforts are made to prevent and treat wound infections.[145,146] The 
expectation is that many studies will investigate the role of micro- 
organisms in skin diseases and therapeutic strategies to treat these 
conditions. As an alternative for research animals in vitro human skin 
models will be the main tool to investigate the interaction between 
micro- organisms and human epidermis.
Since the turn of the century, several in vitro studies have shown 
direct interactions of skin- specific micro- organisms with kerati-
nocytes. These studies revealed that commensal and pathogenic 
bacteria can activate different signalling pathways and are able to 
induce the expression of AMPs and proinflammatory cytokines and 
chemokines in these submerged cultures[13,16,147-152] and that they 
can biphasically influence TJ barrier function.[102] As there is no SC 
in conventional monolayer cultures, the bacteria are in direct con-
tact with the keratinocytes, something that usually does not hap-
pen. Therefore, 3D models mimicking human skin to study in vitro 
infection and host- microbiome interactions are preferable. Until 
now, a few of such studies are performed. One of the first studies 
reported that virulent, hyphae forming, Candida albicans strains pen-
etrate the protective layer of keratinocytes in in vitro reconstructed 
human skin and invade through the epithelial cell layers.[153] Others 
generated a living skin model that supported topical application and 
colonization of skin commensals (eg S. epidermidis) and a transient 
bacterial pathogen (S. aureus) for up to 72 hours of incubation and 
with an intact and undamaged surface showing differential host- 
defense gene expression or TJ protein localization and barrier func-
tion in response to S. epidermidis or S. aureus.[102,154,155] Furthermore, 
3D models were used to study the fundamental effects of biofilms in 
wound healing[156] and to mimic thermal wound infection.[157]
However, in all above- mentioned studies just single bacterial 
strains are used not really reflecting our complex human skin micro-
biome. Future studies should focus on small composite microbiomes 
and patient- derived (whole) skin microbiomes. To eventually perform 
whole microbiome modulation and analysis in vitro the optimal col-
lecting method of micro- organisms and time of coculture should be 
established. Thereafter, the interaction of HEEs with defined bacterial 
strains, small composite artificial and whole (patient- derived) micro-
biomes should be characterized to determine the stability of the in 
vitro microbiomes in time and epidermal host response. The viability 
of relevant bacterial strains upon coculture with the HEEs should be 
determined, as the molecular approaches that are currently in use are 
unable to distinguish between microbial genomic DNA derived from 
living vs dead organisms. We recently successfully used the propidium 
monoazide (PMA) treatment of micro- organisms, resulting in isolation 
and amplification of viable cell genomic DNA only.[158] Finally, the 
window of opportunity for evaluating the effect of pre- , pro- or anti-
biotic strategies in vitro skin microbiome models could be examined.
6  | CONCLUSIONS AND PERSPEC TIVE
Three- dimensional skin models enable us to control and change dif-
ferent parameters of the skin, for example culture stimuli, cell geno-
type or application of therapeutics and measure the impact of those 
on skin barrier function. The 3D skin models available to date will 
certainly advance over the coming years by the optimization of cul-
ture conditions, but already now in vitro cultured 3D skin models 
have been proven to be an excellent alternative for, or addition to, 
experimental animal models to study skin biology, wound healing, 
skin ageing and disease pathology.[96,159-163] As mentioned before, 
improving the actual skin barrier function of 3D skin models needs 
serious attention. One could speculate that the sterile environment 
of cultured 3D skin models lacks important stimuli for a normal skin 
barrier function to be established. The host- microbe interaction be-
tween keratinocytes and microbiota could be a key factor for achiev-
ing the skin barrier function we observe in native skin. The sensing of 
microbial- derived molecules may be an essential trigger for the cor-
rect formation of the skin barrier in 3D skin models. Thus far, studies 
that include microbial components onto 3D skin models are scarce 
and have only investigated the effects of individual microbes on 
TEER, TJ expression and function and host- defense gene expression 
by keratinocytes. Studies on the effects of complete microbiomes 
on SC formation, composition and permeability or the keratinocyte 
interaction with immune cells are pivotal but still missing. Future re-
search should be directed towards the standardization of application 
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methods, controlling bacterial growth and survival on the models, 
and optimizing techniques for the analysis of the microbes and 3D 
skin models.
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